13:36:36 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Nanexa är ett drug delivery-bolag med en egenutvecklad och patenterad drug delivery plattform PharmaShell® som används för formulering av injicerbara depåläkemedel som skapar en jämn tillförsel av läkemedel till blodet under en längre tid. PharmaShell processen baseras på ALD (Atomic Layer Deposition) teknologin som innesluter läkemedelspartiklar med ett tunt skal och skapar möjlighet för läkemedelsbolag att utveckla helt nya läkemedelsprodukter. Nanexa har idag samarbete med flertalet läkemedelsbolag.

Kalender

2022-02-17 Bokslutskommuniké 2021
2021-11-10 Kvartalsrapport 2021-Q3
2021-08-20 Kvartalsrapport 2021-Q2
2021-05-06 Kvartalsrapport 2021-Q1
2021-05-03 Ordinarie utdelning NANEXA 0.00 SEK
2021-02-18 Bokslutskommuniké 2020
2020-11-12 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-06-03 Ordinarie utdelning NANEXA 0.00 SEK
2020-06-02 Årsstämma 2020
2020-05-15 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2019-11-12 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-06-12 Ordinarie utdelning NANEXA 0.00 SEK
2019-06-11 Årsstämma 2019
2019-05-15 Kvartalsrapport 2019-Q1
2019-02-20 Bokslutskommuniké 2018
2018-11-12 Kvartalsrapport 2018-Q3
2018-08-22 Kvartalsrapport 2018-Q2
2018-05-30 Ordinarie utdelning NANEXA 0.00 SEK
2018-05-29 Årsstämma 2018
2018-05-15 Kvartalsrapport 2018-Q1
2018-02-20 Bokslutskommuniké 2017
2017-11-10 Kvartalsrapport 2017-Q3
2017-10-23 Extra Bolagsstämma 2017
2017-08-24 Kvartalsrapport 2017-Q2
2017-06-13 Ordinarie utdelning NANEXA 0.00 SEK
2017-06-12 Årsstämma 2017
2017-05-17 Kvartalsrapport 2017-Q1
2017-02-15 Bokslutskommuniké 2016
2016-11-16 Kvartalsrapport 2016-Q3
2016-08-17 Kvartalsrapport 2016-Q2
2016-05-27 Ordinarie utdelning NANEXA 0.00 SEK
2016-05-26 Årsstämma 2016
2016-05-12 Kvartalsrapport 2016-Q1
2016-04-06 Extra Bolagsstämma 2016
2016-02-25 Bokslutskommuniké 2015
2015-11-19 Kvartalsrapport 2015-Q3
2015-08-20 Kvartalsrapport 2015-Q2
2021-06-11 16:45:00

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONGKONG, JAPAN, NEW ZEELAND, SINGAPORE, SOUTH AMERICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE SECTION “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE.

On 7 June 2021, the board of directors of Nanexa AB (publ) (”Nanexa” or the ”Company”), based on the authorisation granted by the annual general meeting on 24 May 2021, resolved on a rights issue of shares with preferential rights for the Company’s existing shareholders of approximately SEK 126.7 million (the “Rights Issue”). In connection with the Rights Issue, Nanexa has prepared an EU growth prospectus which today has been approved by the Swedish Financial Supervisory Authority and published on the Company’s website www.nanexa.com.

Publishing of EU growth prospectus
The prospectus has been prepared in connection with the Rights Issue and has been approved by the Swedish Financial Supervisory Authority today. The prospectus is available at the website of the Company (www.nanexa.com) and at the website of ABG Sundal Collier, under the section “Ongoing transactions” (www.abgsc.com). The prospectus will also, in a few days, be available on the website of the Swedish Financial Supervisory Authority (www.fi.se/sv/vara-register/prospektregistret/).

In addition to the Rights Issue, the board of directors of the Company may, based on the authorisation granted by the annual general meeting on 24 May 2021, resolve on an over-allotment issue of up to approximately SEK 23.5 million (the “Over-allotment Issue”), conditional upon the Rights Issue being oversubscribed. If the board resolves on the Over-allotment Issue, such resolution is expected on 7 July 2021. For complete information on the Rights Issue and the Over-allotment Issue, please refer to the prospectus.

Registration forms for subscription of issued new shares without subscription rights can be obtained from Aktieinvest by telephone (+46 8 5065 1795) or via email (emittentservice@aktieinvest.se), from the first day of the subscription period (17 June 2021).

The prospectus has been prepared in accordance with Regulation (EU) 2017/1129 of the European Parliament and of the Council (the "Prospectus Regulation"). The Prospectus has been approved by the Swedish Financial Supervisory Authority in accordance with the Prospectus Regulation. The Swedish Financial Supervisory Authority approves the prospectus only to the extent that it meets the requirements for completeness, comprehensibility and consistency specified in the Prospectus Regulation. The approval should not be regarded as any kind of support for the Company or support for the quality of the securities referred to in the prospectus and does not mean that the Swedish Financial Supervisory Authority guarantees that the factual information in the prospectus is correct or complete. Each investor is requested to make his or her own assessment of whether it is appropriate to subscribe for shares in the Rights Issue.

Timetable for the Rights Issue

  • June 10, 2021: Last day of trading in the share, including the right to receive subscription rights.
  • June 11, 2021: First day of trading in the share, excluding the right to receive subscription rights.
  • June 14, 2021: Record date for participation in the Rights Issue, i.e. holders of shares who are registered in the share register maintained by Euroclear Sweden AB on this date will receive subscription rights for participation in the Rights Issue with preferential right.
  • June 17 – June 28, 2021: Trading in subscription rights.
  • June 17 – July 1, 2021: Subscription period.
  • July 7, 2021: Expected day for publication of the outcome of the Rights Issue and the board of directors’ decision to resolve on the Over-allotment Issue.
  • July 19, 2021: Expected day for conversion of BTA (paid and subscribed for shares) to shares and admission of the newly issued shares to trading on Nasdaq First North Growth Market.

Advisors
ABG Sundal Collier is the sole global coordinator and bookrunner in connection with the Rights Issue. Advokatfirman Lindahl KB is legal advisor to the Company.

Important information
The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer to sell or an offer to buy or subscribe for shares issued by the Company in any jurisdiction where such offer or invitation would be illegal. In a member state within the European Economic Area ("EEA"), securities referred to in the press release may only be offered in accordance with applicable exemptions under Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the “Prospectus Regulation”).

This press release is not an offer or invitation to acquire or subscribe for shares or other securities in the United States. The securities that have been mentioned in this release may not be sold in the United States without registration, or without application of an exception from registration, according to the applicable U.S. Securities Act from 1933 (“Securities Act”), or as a part of a transaction that is not covered by the registration requirements according to the Securities Act. There is no intention to register any shares or securities mentioned herein in the United States or to announce a public offering of such securities in the United States. The information in this press release may not be published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or into the United States of America, Australia, Japan, Canada, Hong Kong, New Zealand, Switzerland, Singapore, South Africa, South Korea or any other jurisdiction in which the release, publication or distribution of this information would be unlawful or where such action is subject to legal restrictions or would demand additional registration or other actions according to Swedish law. Acts in contrary to this instruction may constitute a crime according to applicable securities laws.

This release is not a prospectus in accordance to the definition in the Prospectus Regulation as has not been approved by any regulatory authority. In order for investors to fully understand the potential risks and benefits associated with a decision to participate in the Rights Issue, any investment decision should only be made based on the information in the prospectus. Thus, investors are encouraged to review the prospectus in its entirety. This press release constitutes an advertisement in accordance with article 2 k of the Prospectus Regulation. Nanexa has not authorized any offer to the public of shares or rights in any other member state of the EEA than Sweden. This announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in shares. An investment decision to acquire or subscribe for shares in the Rights Issue shall only be made based on publicly available information.

To the extent this press release contains forward-looking statements, such statements does not constitute facts and are characterized by words such as “shall”, “expect”, “believe” “assess”, “intend”, “estimate” and similar expressions. Such statements reflect Nanexa’s intentions, views or present expectations or assumptions. Such forward-looking statements are based on Nanexa’s current plans, estimates and projections, which have been made to the best of Nanexa’s ability. However, Nanexa does not assert that these statements will be correct in the future. Forward-looking statements are associated with risks and uncertainties which are difficult to predict and which generally cannot be affected by Nanexa. It should be contemplated that actual events or outcomes may differ materially from what is included or expressed in such forward-looking statements.